UBS cuts Enovis stock price target on acquisition impact

UBS reduced its Enovis Corp stock price target to $44 from $51, while keeping a Buy rating. This reflects the impact of Enovis's acquisition of eCential Robotics and broader seasonal factors. The shares are currently at $18.43, suggesting a potential 138% upside to the new target, although the stock has fallen 44.5% over the past year and is near a 52-week low of $17.30.

UBS adjusted its estimates to account for about 150 basis points of deal-related dilution to 2027 adjusted EBITDA margins, with 50 basis points of underlying business improvement expected to offset part of the acquisition impact. This would result in a 100 basis points headwind to margins in 2027, after which the company anticipates a return to year-over-year improvement in 2028.

The $44 target was calculated using a 1.5x enterprise value-to-sales multiple, down from the previous 2x multiple. The lower multiple is due to peer group derating and a higher rates macro environment. Enovis reported Q2 2026 adjusted earnings of $0.90 per share, exceeding expectations, but investor sentiment remains cautious due to near-term outlook and cost pressures.

Recent price adjustments by BMO Capital ($27 from $30) and Citizens ($47 from $55) also reflect similar concerns.